Shares of STERIS plc (NYSE:STE – Get Rating) have been given an average recommendation of “Buy” by the nine research firms that are presently covering the firm, MarketBeat.com reports. Eight investment analysts have rated the stock with a buy recommendation. The average 12-month price objective among brokers that have covered the stock in the last year is $260.57.
Several equities research analysts have commented on STE shares. Piper Sandler started coverage on shares of STERIS in a research note on Thursday, July 14th. They issued an “overweight” rating and a $240.00 price target on the stock. StockNews.com upgraded shares of STERIS from a “hold” rating to a “buy” rating in a report on Wednesday, June 15th. Wolfe Research initiated coverage on shares of STERIS in a report on Tuesday, April 5th. They issued an “outperform” rating and a $275.00 price objective for the company. Finally, TheStreet cut shares of STERIS from a “b-” rating to a “c” rating in a report on Thursday, June 16th.
Insiders Place Their Bets
In other STERIS news, VP John Adam Zangerle sold 2,659 shares of the stock in a transaction that occurred on Wednesday, June 15th. The shares were sold at an average price of $205.31, for a total value of $545,919.29. Following the completion of the sale, the vice president now owns 27,936 shares in the company, valued at approximately $5,735,540.16. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders own 1.14% of the company’s stock.
Institutional Inflows and Outflows
STERIS Price Performance
STE opened at $222.51 on Tuesday. The firm has a market cap of $22.27 billion, a price-to-earnings ratio of 93.10 and a beta of 0.71. STERIS has a fifty-two week low of $192.40 and a fifty-two week high of $255.93. The company’s 50-day moving average price is $214.11 and its 200 day moving average price is $225.65. The company has a quick ratio of 1.41, a current ratio of 2.04 and a debt-to-equity ratio of 0.45.
STERIS (NYSE:STE – Get Rating) last released its quarterly earnings data on Wednesday, May 11th. The medical equipment provider reported $2.04 earnings per share for the quarter, topping the consensus estimate of $2.00 by $0.04. The firm had revenue of $1.21 billion for the quarter, compared to analyst estimates of $1.18 billion. STERIS had a net margin of 5.32% and a return on equity of 11.85%. As a group, sell-side analysts expect that STERIS will post 8.71 earnings per share for the current year.
STERIS Increases Dividend
The business also recently announced a quarterly dividend, which will be paid on Friday, September 23rd. Shareholders of record on Wednesday, September 7th will be given a $0.47 dividend. This is an increase from STERIS’s previous quarterly dividend of $0.43. The ex-dividend date is Tuesday, September 6th. This represents a $1.88 dividend on an annualized basis and a yield of 0.84%. STERIS’s dividend payout ratio is presently 71.97%.
About STERIS
STERIS plc provides infection prevention and other procedural products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; accessories for gastrointestinal (GI) procedures, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.
See Also
- Get a free copy of the StockNews.com research report on STERIS (STE)
- MarketBeat Podcast: Find Investing Opportunities For The Rest of 2022
- The Colgate-Palmolive Growth Outlook BrightensÂ
- Deep Value High Yield Newell Brands Is Ready To BottomÂ
- These Stocks Outperformed Last Time There Was A Recession
- Does Rivian’s Stock Still Have A Future?
Want More Great Investing Ideas?
- Bear Market Game Plan!
- The 10 Best Stocks to Own in 2022
- 7 Stocks to Buy and Hold Forever
- 3 Stocks to DOUBLE This Year
Receive News & Ratings for STERIS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for STERIS and related companies with MarketBeat.com's FREE daily email newsletter.